Abstract:Background: Clozapine is the recommended antipsychotic for treatment-resistant schizophrenia (TRS) but there is significant variability between patients in the degree to which clozapine will improve symptoms. The biological basis of this variability is unknown. Although clozapine has efficacy in TRS, it can elicit adverse effects and initiation is often delayed. Identification of predictive biomarkers of clozapine response may aid initiation of clozapine treatment, as well as understanding of its mechanism of action. In this article we systematically review prospective or genetic studies of biological predictors of response to clozapine. Methods: We searched the PubMed database until 20th January 2018 for studies investigating "clozapine" AND ("response" OR "outcome") AND "schizophrenia." Inclusion required that studies examined a biological variable in relation to symptomatic response to clozapine. For all studies except genetic-studies, inclusion required that biological variables were measured before clozapine initiation. Results: Ninety-eight studies met the eligibility criteria and were included in the review, including neuroimaging, blood-based, cerebrospinal fluid (CSF)-based, and genetic predictors. The majority (70) are genetic studies, collectively investigating 379 different gene variants, however only three genetic variants (DRD3 Ser9Gly, HTR2A His452Tyr, and C825T GNB3) have independently replicated significant findings. Of the non-genetic variables, the most consistent predictors of a good response to clozapine are higher prefrontal cortical structural integrity and activity, and a lower ratio of the dopamine and serotonin metabolites, homovanillic acid (HVA): 5-hydroxyindoleacetic acid (5-HIAA) in CSF. Conclusions: Recommendations include that future studies should ensure adequate clozapine trial length and clozapine plasma concentrations, and may include multivariate models to increase predictive accuracy.

A study on the association between T102C polymorphism in the 5-HT2a receptor gene and responses to clozapine

Significant Linkage and Association Between a Functional (gt)n Polymorphism in Promoter of the N-methyl-D-aspartate Receptor Subunit Gene (GRIN2A) and Schizophrenia.

The Relationship Between Drd2 Gene Polymorphisms (c957t and C939t) and Schizophrenia: A Meta-Analysis

COMT, 5-HTR2A, and SLC6A4 Mrna Expressions in First-Episode Antipsychotic-Naïve Schizophrenia and Association with Treatment Outcomes

Analysis of the Association Between T102c Polymorphism of the Serotonin 2a Receptor Gene and Schizophrenia in the Chinese Population.

Clinical Characteristics and Association Analysis of Serotonin 2A Receptor Gene T102C Polymorphism with Obsessive Compulsive Symptoms in Three Different Conditions

Pharacogenetic Effects of Dopamine Transporter Gene Polymorphisms on Response to Chlorpromazine and Clozapine and on Extrapyramidal Syndrome in Schizophrenia

Study on the relationship between serotonin receptor 2A gene polymorphism and clinical response to paroxetine

Association between SREBF2 gene polymorphisms and metabolic syndrome in clozapine-treated patients with schizophrenia.

Impact of Pharmacogenetic Testing on Clozapine Treatment Efficacy in Patients with Treatment-Resistant Schizophrenia

5-Htr1a And 5-Htr2a Genetic Polymorphisms And Ssri Antidepressant Response In Depressive Chinese Patients

Association Studies of Genomic Variants with Treatment Response to Risperidone, Clozapine, Quetiapine and Chlorpromazine in the Chinese Han Population

[Molecular Pharmacogenetic Studies of Drug Responses to Obsessive-Compulsive Disorder and Six Functional Genes].

The --1019 C/G Polymorphism of the 5-HT(1)A Receptor Gene is Associated with Negative Symptom Response to Risperidone Treatment in Schizophrenia Patients.

102T/C SNP in the 5-Hydroxytryptamine Receptor 2A (HTR2A) Gene and Schizophrenia in Two Southern Han Chinese Populations: Lack of Association.

Cortical Surface Area Correlates With Ston2 Gene Ser307pro Polymorphism In First-Episode Treatment-Naive Patients With Schizophrenia

Response To Chlorpromazine Treatment May Be Associated With Polymorphisms Of The Drd2 Gene In Chinese Schizophrenic Patients

Biological Predictors of Clozapine Response: A Systematic Review

Genetic Risk of Clozapine Induced Leukopenia and Neutropenia: A Genome-Wide Association Study

Association study on 5-HT 2A receptor gene T102C polymorphism and the concentration of gray matter in patients with major depressive disorder

Association between a COMT polymorphism and clinical response to risperidone treatment: a pharmacogenetic study.